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phenotype is believed to positively impact obesity and insulin resistance. Here we show that the soluble form
of the extracellular domain (ECD) of C-type lectin-like receptor 2, CLEC2, regulates Kupffer cell polarization in
the liver and improves glucose and lipid parameters in diabetic animal models. Over-expression of
Fc-CLEC2(ECD) in mice via in vivo gene delivery, or injection of recombinant Fc-CLEC2(ECD) protein, results in
a reduction of blood glucose and liver triglyceride levels and improves glucose tolerance. Furthermore,
Fc-CLEC2(ECD) treatment improves cytokine proﬁles and increases both the M2 macrophage population and
the genes involved in the oxidation of lipid metabolism in the liver. These data reveal a previously unidentiﬁed
role for CLEC2 as a regulator of macrophage polarity, and establish CLEC2 as a promising therapeutic target for
treatment of diabetes and liver disease.
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Chronic inﬂammation is thought to contribute to the development
of obesity and metabolic syndromes (Hotamisligil, 2006; Shoelson
et al., 2006). Aberrant pro-inﬂammatory immune responses are found
in many organs of diabetic individuals, including the pancreas, liver,
adipose, heart, brain, and muscle (Lumeng and Saltiel, 2011). For
example, many pro-inﬂammatory proteins, including TNF-α, interleukin
6 (IL-6) and inducible nitric oxide synthase, secreted from adipose tissue
macrophages (ATM), are found at higher levels in adipose tissue from
obese individuals compared to lean individuals (Harkins et al., 2004;
Hotamisligil, 2006). Increased adiposity promotes macrophage inﬁltra-
tion and local inﬂammation, which in turn contributes to increasing
insulin resistance (Weisberg et al., 2003; Xu et al., 2003). Inﬂammatory
responses in the liver, another major metabolic organ, have also been
implicated in obesity, type 2 diabetes and fatty liver diseases. Activation
of the residentmacrophages in the liver, Kupffer cells, induces hepatotox-
icity in obesemice (Li andDiehl, 2003) and regulates hepatic glucoseme-
tabolism and insulin resistance (Huang et al., 2010; Lanthier et al., 2010).
Macrophages are derived from monocyte precursors and undergo
speciﬁc differentiation and activation depending on the local tissueThis is an open access article under tenvironment and cytokine milieu (Steinman and Idoyaga, 2010). Two
distinct states of polarized activation for macrophages have been
deﬁned: the classically activated macrophage phenotype, M1, and the
alternatively activated macrophage phenotype, M2 (Gordon and
Taylor, 2005; Mantovani et al., 2002). M1 macrophages are effector
cells in TH1 cellular immune responses, whereas M2 macrophages
appear to promote immune suppression and wound healing/tissue
repair (Gordon and Taylor, 2005; Mantovani et al., 2002). Recent
evidence demonstrates that in lean animals, higher numbers of macro-
phages are M2 polarized, possessing anti-inﬂammatory potential by
producing IL-10, while obesity drives pro-inﬂammatory M1 polariza-
tion (Lumeng et al., 2007a,b; Mjosberg et al., 2011). Thus, the M1/M2
switch may occur within local tissues such as fat and liver (Kang et al.,
2008; Odegaard et al., 2008), and the balance between M1 and M2
macrophages contribute to the onset of insulin resistance (Charo,
2007; Lumeng et al., 2007a,b). Locally produced TH2-type cytokines,
such as IL-4 and IL-13, and activation of peroxisome proliferator-
activated receptor δ/β (PPARδ/β) or PPARγ, result in the activation of
M2 macrophages. Disruption of either PPARδ/β or PPARγ in myeloid
cells may impair the alternative activation of M2 macrophages in the
adipose tissue and liver, resulting in impaired glucose tolerance and
exacerbated insulin resistance under high fat diet conditions (Hevener
et al., 2007; Kang et al., 2008; Odegaard et al., 2007, 2008).
C-type lectin-like receptor 2 (CLEC2)was initially identiﬁed through
a computational approach searching for sequences similar to knownhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2000). CLEC2, a member of the type II transmembrane C-type lectin-
like receptor family, has a single YXXL/hemi-ITAM (immuno-receptor
tyrosine-based activationmotif)within its cytoplasmic domain. Expres-
sion of CLEC2has beendetected on the surface of platelets and a number
of different immune cells, including dendritic cells, neutrophils, and
Kupffer cells (Colonna et al., 2000; Mourao-Sa et al., 2011; Tang et al.,
2010). The gene encoding CLEC2 is located in a genetic locus proximal
to a distinct cluster of related receptors, including CLEC7A, LOX-1 and
CLEC9A; most of which are expressed in myeloid populations
(Sobanov et al., 2001).
The ﬁrst identiﬁed ligand for CLEC2 was rhodocytin, a toxin from
snake venom that induces platelet aggregation (Hooley et al., 2008;
Suzuki-Inoue et al., 2006). More recently, podoplanin, a membrane
glycoprotein, was proposed as an endogenous ligand for CLEC2
(Christou et al., 2008; Kato et al., 2008; Suzuki-Inoue et al., 2007). The
interaction between CLEC2 and podoplanin is critical for the separation
of blood and lymphatic vessels during embryonic development and dur-
ing some pathophysiological conditions, such as tumor metastasis
(Bertozzi et al., 2010). The interaction between the two proteins during
embryogenesis is exempliﬁed by the ﬁnding that mice deﬁcient for
CLEC2 display a similar phenotype as mice deﬁcient for podoplanin,
including bleeding and defects in vascular connections. However, in
the normal adult state, while CLEC2 is predominantly expressed on
cells located within blood vessels, podoplanin is expressed on cells
lining lymphatic vessels (Suzuki-Inoue et al., 2007) and thus interaction
between the two is unlikely. Therefore, it is possible that other, yet
unidentiﬁed CLEC2 ligands may exist.
Besides playing a role in platelet aggregation (Chang et al., 2010;
Kerrigan et al., 2009; Mourao-Sa et al., 2011), a function for CLEC2 on
other immune cells has yet to be deﬁned. Here we show that soluble
CLEC2 regulates Kupffer cell polarization in the liver and improves
glucose and lipid parameters in diabetic animals, thus revealing a novel
physiological role for CLEC2 in both inﬂammation and metabolism. Our
results demonstrate a previously unknown connection between CLEC2
andglucose and lipidmetabolism, and support CLEC2 as a potential target
for treating diabetes.
2. Materials and Methods
2.1. Fc-CLEC2(ECD)
To design a stable soluble CLEC2 protein that may block endogenous
CLEC2 activity, the C-terminal extracellular domain of murine CLEC2
(51-229)was fusedwith a human Fc protein at its N-terminus connect-
ed by a ﬂexible glycine linker (G4SG4), yielding Fc-CLEC2(ECD). DNA
vectors for hydrodynamic injection, recombinant AAV preparation and
recombinant protein expression all carry the same coding sequence
for this Fc-CLEC2(ECD) protein. Recombinant Fc-CLEC2(ECD) was
expressed through transient transfection of HEK293 cells and puriﬁed
via Protein A afﬁnity chromatography.
2.2. Animal Studies
All animal experiments were approved by the Institutional Animal
Care and Use Committee of Amgen and cared for in accordance to the
Guide for the Care and Use of Laboratory Animals, 8th Edition (National
Research Council (U.S.). Committee for the Update of the Guide for the
Care and Use of Laboratory Animals. et al., 2011). Mice were housed in
an air-conditioned room at 22 ± 2 °C with a 12 hour light and
12hour darkness cycle (0600–1800 h).Micewere randomized into con-
trol and treatment groups to achieve similar baseline levels of body
weight, fasting glucose and insulin levels. No animals were excluded
from the statistical analysis, and data collection was blinded in the
studies.The efﬁcacy of recombinant Fc-CLEC2(ECD) protein was tested in
14-week-old, male B6D2F1/J mice (The Jackson Laboratory) fed for at
least 8 weeks with a 60% fat diet, D12492 (Research Diet). The mice
received intraperitoneal injection of Fc-CLEC2(ECD) protein diluted in
0.2 ml PBS. The control group received intraperitoneal injections of
PBS. Injections were performed 1 to 2 h prior to the dark phase of the
light cycle except on days when oral glucose tolerance test (oGTT)
was performed. Proteins were then administered 2–3 h before fasting
glucose measurement.
Hydrodynamic Tail Vein (HTV) studieswere carried out in 12-week-
old male B6D2F1/J mice (The Jackson Laboratory) fed with a 60% high
fat diet for 6 weeks. Mice were randomized in respective groups based
on body weight and both fasting (4 h) blood glucose and serum insulin
levels, all of whichmeasured the day before HTV injection. An endotox-
in free DNA construct expressing Fc-CLEC2(ECD) was diluted in a saline
solution to the concentration of 8 μg/ml. The injection volume was
calculated based on body weight, approximately 100 ml/kg, but never
exceed 2.5 ml per animal. The DNA solution was injected into the tail
vein of mice within a 5–8 second timeframe. The construct carrying
human Fc protein alone was used as a negative control.
Recombinant adeno-associated virus (rAAV) expressing Fc-
CLEC2(ECD) was produced by transient transfection into 293T cells
using the helper-free system, puriﬁed by gradient centrifugation, buffer
exchanged. Mice were injected through the tail vein with 2–8 × 1012
virus particles per mouse of either Fc-CLEC2(ECD), or an empty vector
(EV) as the negative control, in PBS.
An oGTT was performed after 4 h of fasting. Micewere injectedwith
a bolus of glucose (10ml/kg bodyweight of 20% glucose) into the stom-
ach by a gavage needle (20G×1.5 in.) (Popper and Sons). Blood glucose
levels were measured with a glucometer from tail tip blood collected at
0, 20, 40, 60, and 90min after glucose dosing. Serum insulin levels were
measured using a mouse insulin ELISA kit (ALPCO Diagnostics). The
assay was performed as described by the manufacturer's protocol.
Hepatic triglyceride content was determined using homogenized
liver extracts using chloroform/methanol (2:1 v/v) and lysed using a
Qiagen tissue lyzer for 30 s to 1 min. Samples were ﬁrst transferred to
12 × 75 mm glass test tubes and incubated at room temperature for
30–45 min. Samples were then washed with 50 mM NaCl, vortexed,
centrifuged at 1500 g for 10 min and the organic phase was removed
and placed into a new glass tube. The organic phase was washed twice
with 0.36 M CaCl2/methanol and centrifuged at 1500 g for 10 min. The
triglyceride levels were measured using an Inﬁnity triglyceride assay
kit (Thermo Scientiﬁc).
Serum cytokine measurements were performed using the Bio-Plex
Pro cytokine multiplex assay (BioRad) to measure the levels of
cytokines in serum samples. Samples were diluted 2-fold in Bio-Plex
sample diluent for the assay. The assay was performed according to
the manufacturer's protocol. Plates were read on a Bio-Plex system
and data was obtained using Bio-Plex Manager software.2.3. H&E Staining and Immunohistochemistry
All collected tissues were ﬁxed in 10% Neutral Buffered Formalin
(NBF) for 24 h, processed to parafﬁn blocks, and cut into 4 micron
sections. The sections were dried overnight in a 37 °C oven, followed
by 1 hour incubation in a 60 °C oven prior to deparafﬁnization.
Deparafﬁnization and H&E staining (Surgipath, Buffalo Grove, IL, USA)
were performed on an automated multistainer (Leica ST 5020, Buffalo
Grove, IL, USA). The F4/80 antibody, an IgG2b afﬁnity puriﬁed ratmono-
clonal antibody,waspurchased fromAbDSerotec. Theα smoothmuscle
actin antibody was purchased from Abcam.Morphometric analysis was
performed using a Scan Scope XT (Aperio) and both Image Scope
(Aperio) and Indica Lab (Indica Lab) software. For each animal, nine
3.6 × 105 μm2 areas were evaluated for the percent F4/80 positive
staining per area of tissue.
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Microtiter plates were coated with 1.0 μg/ml of goat anti-human Fc
(Jackson ImmunoResearch) in PBS overnight at 4 °C, and washed one
time with PBS. The plates were then blocked with 3% BSA in PBS over
night at 4 °C, and washed one time with PBS. Serum samples were
diluted in PBS + 1% BSA and incubated for 1 h at room temperature
and washed 3 times with PBS + 0.01% Tween-20. Goat anti-human
Fc-HRP (Jackson ImmunoResearch) in PBS+ 1% BSAwas added and in-
cubated for 1 h at room temperature. The plates were washed 6 times
with PBS+0.01% Tween-20 and developedwith tetramethyl benzidine
(TMB) as substrate. 1 N HCl was added as the stop solution. The results
were read on a SpecMaxplate reader at 450nm. Recombinant human Fc
protein (Jackson ImmunoResearch) was used for standard curve.
2.5. Macrophage Isolation
Resident peritoneal macrophages were extracted from 6–10-
week-old C57BL/6 mice and incubated at 37 °C for 2 h prior to
stimulation. Thioglycolate-elicited macrophages were prepared by
injecting 2-month-old C57BL/6 mice with 2 ml 3% aged thioglycolate
media. On day 4, cells were isolated by and prepared for resident
macrophages.
2.6. Quantitative RT-PCR (RT-qPCR)
Human andmouse tissue total RNAs were purchased from Clontech,
BioChain Institute, Inc. and Agilent Technologies. Mouse total RNA from
hepatocytes and liver non-parenchymal cells was obtained from
Zen-Bio. Other tissue or Cell Total RNA was isolated using QIAcube
andRNeasy kit (Qiagen). Reactionmixtures contained 100ngof isolated
total RNA, 200 nMof each gene speciﬁc primer and probe and Brilliant II
QRT-PCR Master mix (Stratagene) in a total volume of 50 μl. All of the
reactions were performed in duplicate on a Stratagene MX3000p
sequence detection system, and relative mRNA levels were calculated
by the comparative threshold cyclemethodusingGAPDHas the internal
control.
2.7. Cell Cultures and In Vitro Assays
RAW264.7 cells were grown in Dulbecco'smodiﬁed Eagle'smedium
(DMEM) containing 10% fetal bovine serum and 50 μg/ml streptomycin
and penicillin. RAW 264.7 cells were treated with LPS and IL-4 (Sigma)
at a concentration of 100 ng/ml for 24 h prior to harvest.
The platelet aggregation assay was performed on a Chrono-log
Aggregometer. Platelet- rich plasma (PRP)was analyzed in the presence
of either rhodocytin, CLEC2 antibody (Abcam), or with Fc-CLEC2 (ECD).
To prepare PRP, fresh whole blood collected frommice was mixed with
10% ACD (Acid-Citrate-Dextrose) buffer (Sigma) and centrifuged at
100 g for 20 min. PRP was collected from the top layer.
For Kupffer cell/primary hepatocyte co-culture, Kupffer cells from
12–14week oldmale C57BL/6mice (The Jackson Laboratory)were pur-
chased from Cell Speciﬁc (Berkeley, California). Primary hepatocytes
were isolated and cultured using Invitrogen liver media and reagents.
In brief, animals were CO2 treated for 2 min until no detectable breath-
ing and pinned down with needles. After opening the abdomen, a 16G
catheter was gently inserted into the portal vein and, simultaneously,
the interior vena cava vein was severedwith scissors. The liverwas per-
fused with 30 ml of pre-warmed perfusion media, followed by 30ml of
liver digestionmedia. After perfusion, the liver was removed and rinsed
with washingmedia. Forceps were used to peel off the liver capsule and
gently shake out hepatocytes. Hepatocytes were ﬁltered through
100 μm cell strainer into a 50 ml conical tube and then washed 3
times by centrifugation at 500 rpm for 3 min to remove the washing
media. Primary hepatocytes and Kupffer cells were mixed at a 2:1
ratio in M199 culture media and 4 × 105 cells per well were platedinto 6-well plates and incubated at 37 °C. After 48 h, 100 ng/ml of
Fc-CLEC2(ECD) or control was mixed with fresh M199 culture media
and added to the cells. After a 5 hour incubation, cells were harvested
for RNA isolation and RT-qPCR studies.
3. Results
3.1. In Vivo Overexpression of Fc-CLEC2(ECD) Improves Glucose Homeosta-
sis and Attenuates Hepatic Steatosis
During a quest to identify potential novel regulators of metabolism,
we noted the relatively high expression levels of CLEC2 in human liver
samples among a panel of tissues examined (Fig. 1A). Clec2 is also
expressed in the mouse liver tissue although the relative level to other
tissues is not as high as in humans (Fig. 1B). Fractionation of cells
recovered from mouse liver revealed that Clec2 was highly expressed
speciﬁcally in non-parenchymal cells compared to hepatocytes
(Fig. 1C), consistent with the detection of CLEC2 on Kupffer cells (Tang
et al., 2010). As liver plays major roles in the metabolic control of
lipid, glucose, and energy metabolism, we wondered if CLEC2 could
affect metabolism. Since no soluble ligands have been identiﬁed for
CLEC2, we took the approach to overexpress a soluble form of CLEC2,
which could potentially act as a decoy antagonistic receptor as a way
to study CLEC2 function. To achieve a stable and high level expression
of CLEC2, the extracellular domain of murine CLEC2 (residues 51–229)
was fused with human Fc to generate Fc-CLEC2(ECD) (Fig. 2A). Puriﬁed
recombinant Fc-CLEC2(ECD) can bind to the known ligand, rhodocytin,
and block rhodocytin-induced platelet aggregation in vitro (Fig. 2B and
C), demonstrating that this form of CLEC2 is functional. A DNA expres-
sion construct carrying Fc-CLEC2(ECD) was delivered in vivo through
HTV injection in a diet induced obesity (DIO) mouse model. 12-week-
old male B6D2F1/J DIO mice were randomized into two groups based
on body weight and baseline glucose levels. The mice in the treatment
group were injected with the HTV Fc-CLEC2(ECD) DNA construct and
mice in the control group were injected with a DNA construct carrying
Fc alone. The expression of full length Fc-CLEC2(ECD) protein was con-
ﬁrmed by Western blot using an anti-human Fc antibody (data not
shown). Serum exposure was quantitated by ELISA and revealed that
high levels of protein exposure were achieved after HTV delivery
(Fig. 2D). Fc-CLEC2(ECD) did not induce signiﬁcant changes to body
weight during the experiment period (Fig. 2E), while a signiﬁcant
reduction in fasting blood glucose levels was observed 13 days after
Fc-CLEC2(ECD) treatment (Fig. 2F). At day 13, an oGTT demonstrated
a signiﬁcant improvement in the animals expressing Fc-CLEC2(ECD)
compared to the mice in the control group (Fig. 2G). Furthermore,
mice in the treatment group also had signiﬁcantly lowered serum
insulin levels (Fig. 2H), suggesting an improvement in insulin sensitivity.
Because hepatic steatosis is commonly associatedwith obesity and diabe-
tes, livers were collected from the mice at day 18 for triglyceride (TG)
measurement. Liver TG levelswere signiﬁcantly reduced in the treatment
group compared to the control mice (Fig. 2I). No signs of ﬁbrosis were
found in livers from either group as indicated by the negative immuno-
histochemical staining for α smooth muscle actin (αSMA) (Supplemen-
tary Fig. 1A). Histopathological analysis of multiple organs, including
the liver, lymph node, pancreas, skeletal muscle, spleen, and white fat,
also did not reveal any gross abnormalities in mice from either group
(data not shown).
3.2. Fc-CLEC2(ECD) Treatment Increases M2Macrophage Expression in the
Liver
To understand the mechanism leading to the improved glucose and
lipid proﬁles post Fc-CLEC(ECD) treatment, since endogenous Clec2 is
highly expressed in the liver, we performedmicroarray analysis to com-
pare gene expression proﬁles between livers from the Fc-CLEC2(ECD)
treatment group and the control group. Expression analysis revealed
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Fig. 1.High expression of Clec2 in the non-parenchymal fraction of liver cells. (A) RT-qPCR of different human tissues shows CLEC2 enrichment in the testis, liver and PBL. (B) RT-qPCR of
different mouse tissues. (C) Clec2 is highly expressed in non-parenchymal cells of liver compared to hepatocytes. Results are expressed as the mean ± SEM of triplicates and are
representative of two independent experiments.
217X. Wu et al. / EBioMedicine 2 (2015) 214–224that the most regulated genes following treatment included many
macrophage marker genes. Further conﬁrmed by RT-qPCR analysis,
markers of M2 macrophage activation such as Clec7a (the gene
encoding Dectin-1), Chi3l3 (the gene encoding Ym-1), and Retnla (the
gene encoding Fizz-1) were highly induced in the Fc-CLEC2(ECD) treat-
ment group while markers of M1 macrophages such as Tnfα, Il6, and
iNos were not signiﬁcantly changed (Fig. 2J). The induction of M2
markers appeared to be liver speciﬁc as no signiﬁcant changes were
observed in the adipose tissue (Supplementary Fig. 2). Immunohisto-
chemical analysis with the macrophage marker, F4/80, in the liver was
subsequently performed. This analysis revealed an almost two-fold
increase in the F4/80+ staining area of Fc-CLEC2(ECD)-treated mice
versus control mice (Fig. 2K and L), which could be due to either an
increase in macrophage size and/or number. We also observed the
Kupffer cells in the treatment group to be more widely distributed
throughout the sinusoids, with an increase in plump cells and clusters
around degenerating hepatocytes compared to control mice (Fig. 2K).
3.3. In Vivo Overexpression of Fc-CLEC2(ECD) Delivered by rAAV Improves
Glucose Homeostasis
Since the method of HTV injection can induce acute hyper perfusion
in the liver, in order to rule out that the observed changes in Kupffer
cells were not due to, or enhanced because of the HTV treatment, we
used rAAV to overexpress Fc-CLEC2(ECD). B6D2F1/J-DIO mice were
injected with either rAAV expressing Fc-CLEC2(ECD) or rAAV containing
an empty vector (EV) as the negative control. Similar to the HTV results,
no obvious bodyweight difference between the two groupswas detected
during the experiment period (Fig. 2M), while mice injected with
Fc-CLEC2(ECD) demonstrated signiﬁcant improvements in oGTT
(Fig. 2N) and lower serum insulin levels (Fig. 2O) compared to the controlgroup. The effects of Fc-CLEC2(ECD) in the leptin deﬁcient ob/obmouse
model were also performed. Six-week-old male ob/ob mice injected
with Fc-CLEC2(ECD) did not exhibit any signiﬁcant body weight
difference compared to control mice (Fig. 2P), while they had lower
fasting glucose levels (Fig. 2Q) and showed an improvement in the
oGTT (Fig. 2R). In sum, the overexpression of Fc-CLEC2(ECD) using
rAAV led to improved glucose homeostasis in two different mouse
models; these results are consistent with those observed when HTV
was used as a gene delivery method.
3.4. Recombinant Fc-CLEC2(ECD) Protein Improves Glucose and Lipid
Homeostasis
Overexpressing Fc-CLEC2(ECD) using the two in vivo gene delivery
methods revealed a novel function for CLEC2 in regulating glucose
homeostasis. Since both HTV and rAAV drive the expression of the
gene-of-interest mainly from the liver, we next wanted to address
whether injection of recombinant Fc-CLEC2(ECD) proteins could achieve
similar metabolic phenotypes, and thereby establish recombinant
Fc-CLEC2(ECD) as a potential therapy to treat diabetes. Thus, 12-week-
old male B6D2F1/J-DIO mice were injected with 10 mg/kg or 30 mg/kg
of recombinant Fc-CLEC2(ECD) protein or PBS daily. Over the course of
two weeks no apparent body weight differences were observed among
cohorts (Fig. 3A). However, groups treated with Fc-CLEC2(ECD)
manifested either trended (10 mg/kg group) or statistically signiﬁcant
lowering (30 mg/kg group) in plasma insulin levels compared to the
PBS control group (Fig. 3B). Similar to the HTV and rAAV studies, both
recombinant Fc-CLEC2(ECD) protein treatment groups exhibited signiﬁ-
cantly improved glucose tolerance compared to the control group
(Fig. 3C). Both serum TG levels (Fig. 3D) and liver TG content (Fig. 3E)
were lower in groups treatedwith recombinant Fc-CLEC2(ECD) proteins,
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Fig. 2. Improvedglucose and lipid homeostasis after over-expression of Fc-CLEC2(ECD) through in vivo genedelivery. (A) Schematic showing the designof Fc-CLEC2(ECD)molecule. (B–C)
Puriﬁed recombinant Fc-CLEC2(ECD) binds to rhodocytin and blocks rhodocytin induced platelet aggregation. (B) Dose-dependent binding of Fc-CLEC2(ECD) incubated with rhodocytin
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219X. Wu et al. / EBioMedicine 2 (2015) 214–224similar to that observed in the in vivo gene delivery experiments (Fig. 2).
Also, no signs of ﬁbrosis were found in livers as indicated by the negative
immunohistochemical staining for αSMA (Supplementary Fig. 3A).Histopathological analysis of multiple organs, including the fat, skeletal
muscle, and pancreas did not reveal any gross abnormalities in mice
from treatment groups (Supplementary Fig. 3B).
220 X. Wu et al. / EBioMedicine 2 (2015) 214–2243.5. Recombinant Fc-CLEC2(ECD) Simulates M2 Macrophage Activation in
the Liver
Gene expression analysiswas performed on livers from recombinant
Fc-CLEC2(ECD) treated animals. Similar to animals treated by the gene
delivery methods, markers of M2 macrophage activation, Clec7a and
Chi3l3, were increased under the treatment conditions compared to
the control group (Fig. 3F). Immunohistochemical staining with F4/80
to visualize Kupffer cells demonstrated a trending increase in F4/80+
staining area (Fig. 3H). As shown in Fig. 3G, treated mice also showed
plumper Kupffer cells with some clusters surrounding liver fat vacuoles
and some impinging on central vessels similar to HTV injected mice
(Fig. 2K).
Since Kupffer cells aremacrophages that clean up cell debris and en-
dotoxin through phagocytosis, we measured several genes involved in
phagocytosis, including Coro1a, Ctss, Fcgr1 and Itgb2, all of which were
induced in a dose dependent manner (Fig. 3F). Reduced macrophage
phagocytic activity has been reported in several diabetes animalmodels
(Liu et al., 1999; O'Brien et al., 2002) and hepatic phagocytic dysfunction
has been associated with liver steatosis and abnormal cytokine regula-
tion (Yang et al., 1997). Consistent with increased M2 macrophage
markers in animals treated with soluble CLEC2, the level of the M2-
associated anti-inﬂammatory cytokine, IL13, was increased (Fig. 3I).
Moreover, several pro-inﬂammatory cytokines, G-CSF, KC and MIP-1a,
were decreased in the serum (Fig. 3I) indicating that soluble CLEC2
stimulates Kupffer cell M2 activation and phagocytic activity, as well
as suppresses the inﬂammation activity in diabetic animal models.-3 7 1 3
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independent experiments.3.6. Activation of CLEC2 Suppresses M2 Macrophage Marker Expression In
Vitro
To understand whether the observed induction of M2 markers
in vivo is the direct action of Fc-CLEC2(ECD) on Kupffer cells or second-
ary to improvement in glucose metabolism, we explored the effects of
CLEC2 on cultured RAW264.7 cells, amouse leukemicmonocytemacro-
phage cell line. To elucidate the effects of activating CLEC2 on macro-
phages, we utilized an agonistic anti-CLEC2 antibody conﬁrmed by its
ability to induce aggregation of platelets in vitro (Fig. 4A). Treatment
of this anti-CLEC2 agonistic antibody on cultured RAW264.7 cells signif-
icantly suppressed the expression of the M2 marker, Arg1, but did not
change the expression of the M1 marker, Csf2, suggesting that the
activation of endogenous CLEC2 may suppress M2 activation in vitro
(Fig. 4B). To further understand the possible physiological function of
CLEC2, we isolated peritoneal macrophages from diabetic animals to
examine Clec2 expression. Clec2 was highly expressed in ob/ob
macrophages compared to wild type control animals while other
Clec genes showed no difference between cohorts (Fig. 4C). These
observations suggest that, under disease conditions, CLEC2 may
contribute to increased inﬂammation, insulin resistance, and diabe-
tes progression. Therefore, suppression of this pathway may lead to
improvements in metabolic conditions. This is consistent with
the observed improvements in glucose metabolism in animals
treated with the soluble form of CLEC2 (Figs. 2 and 3), which could
potentially act as a decoy receptor to antagonize endogenous receptor
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221X. Wu et al. / EBioMedicine 2 (2015) 214–2243.7. Fc-CLEC2(ECD) Simulates Liver Oxidative Phosphorylation and Fatty
Acid Oxidation
To further explore the impact of CLEC2 function on Kupffer cells and
hepatocytes, we examined expression of a panel of genes after treat-
ment of co-cultured primary hepatocyte and Kupffer cells with soluble
CLEC2. RT-qPCR analyses revealed a profound increase in the expression
of oxidative phosphorylation genes, Ndufs and Sdhb, and enzymes for
fatty acid beta-oxidation, Acox1 and Cpt1a, but not the fatty acid
transporter, Slc27a1. However, hepatocytes alone treated with soluble
CLEC2 in the absence of Kupffer cells displayed no changes on these
genes (data not shown) suggesting that activation of Kupffer cells by
Fc-CLEC2(ECD) promotes oxidative metabolism in hepatocytes
(Fig. 4D). Furthermore, activation of fatty acid oxidationmay contribute
to the observed reduction in liver TG in vivo upon Fc-CLEC2(ECD)
treatment.4. Discussion
Chronic inﬂammation, a hallmark feature of obesity and diabetes
(Hotamisligil, 2006; Shoelson et al., 2006), is in part characterized by
increased macrophage inﬁltration into adipose tissue, which in turn
exacerbates insulin resistance (Weisberg et al., 2003; Xu et al., 2003).
However, two distinct pathways for macrophage activation have beendeﬁned: pro-inﬂammatory M1 macrophages and anti-inﬂammatory
M2 macrophages. Whereas M1 macrophages drive adipose inﬂamma-
tion in obese mice, macrophages residing in the adipose tissue of lean
mice are predominantly of the M2 type and work to actively suppress
inﬂammation (Lumeng et al., 2007a; Odegaard et al., 2007). Activation
of liver-speciﬁc Kupffer cells contributes to liver steatosis and is also
implicated in insulin resistance (Huang et al., 2010; Lanthier et al.,
2010). Similar to adipose resident macrophages, Kupffer cells exhibit
ﬂexibility in that they can be activated toward either a classical pro-
inﬂammatory state or an alternative anti-inﬂammatory state (Odegaard
et al., 2008). Accordingly, alternatively activated M2-polarized Kupffer
cells have been shown to ameliorate obesity-induced insulin resistance
(Odegaard et al., 2008).
Although a role for the C-type lectin-like receptor, CLEC2, in platelet
activation has been well described (Chang et al., 2010; Kerrigan et al.,
2009; Mourao-Sa et al., 2011), a role for CLEC2 in immune cell function
had yet to be elucidated. Among all tissues examined, we observed the
highest expression of Clec2 in the liver, presumably due to expression
on the surface of Kupffer cells (Fig. 1C, Tang et al., 2010). Due to the
lack of known endogenous ligands for CLEC2, we chose to focus on a
loss-of-function study using the soluble CLEC2 ECD as a potential dom-
inant negative factor to block endogenous CLEC2 receptor function.
Using this approach, our resultswere consistent across allmodels tested
and revealed that Fc-CLEC2(ECD) treatment can reproducibly induce
markers of alternatively activated Kupffer cells, including Clec7a, Retnla,
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222 X. Wu et al. / EBioMedicine 2 (2015) 214–224and Chi313, and signiﬁcantly improved glucose and lipid metabolism.
These results suggest that the endogenous CLEC2 receptor may play a
pro-inﬂammatory role under disease conditions which is consistent
with the observation that Clec2 expression in macrophages of diabetic
animals is dramatically increased. Gene expression proﬁling further
showed that Fc-CLEC2(ECD) stimulates a phagocytic activity in the
liver. The liver has a highly developed ﬁltering mechanism to maintainhomeostasis in the circulation and Kupffer cells are key players in this
process (Toth and Thomas, 1992). The Kupffer cells form a protective
barrier for the systemic circulation and removemany harmfulmaterials
such as endotoxins and cellular debris through phagocytosis (Toth and
Thomas, 1992). It is known that under diabetic andmetabolic syndrome
conditions, macrophages display altered immune activities such as
decreased phagocytosis due to insulin resistance (Liang et al., 2007;
223X. Wu et al. / EBioMedicine 2 (2015) 214–224Plotkin et al., 1996), and that dysfunction of the phagocytic activity can
result in the accumulation of materials that cause inﬂammatory
responses and exacerbate insulin resistance. Our results suggest that
Fc-CLEC2(ECD) improves the deﬁciency in Kupffer cell phagocytosis
present under diseased conditions, reduces pro-inﬂammatory cytokine
release, and increases anti-inﬂammatory cytokine production. Given
the important role played by inﬂammation in insulin resistance and
metabolic disorders, our data suggests that the anti-inﬂammatory
activity of Fc-CLEC2(ECD) contributes to the improvement of glucose
and lipid metabolism observed in our studies.
Although the physiological role of CLEC2 in Kupffer cell activation
and phagocytic activity is not completely understood, published studies
support our hypothesis. Kerrigan et al., for example, generated a chime-
ric receptor bearing the extracellular and transmembrane domains of
CLEC7a and the cytoplasmic tail of CLEC2 to investigate CLEC2 function
on neutrophils (Kerrigan et al., 2009). Whether the capacity of the
chimeric protein,when expressed in cell lines, reﬂects the actual endog-
enous function of an intact CLEC2 receptor was not resolved, but the re-
sults indicated that the cytoplasmic tail of CLEC2, at least, couldmediate
a phagocytic activity. In another series of studies, Chang et al. (2010)
showed that rhodocytin speciﬁcally induced macrophage secretion of
proinﬂammatory cytokines, and Mourao-Sa et al. (2011) demonstrated
that cross-linking of an anti-CLEC2 agonistic antibody in myeloid cell
cultures modulated the effects of toll-like receptor (TLR) agonists to
potentiate anti-proinﬂammatory IL-10 production. Thus, several
published reports point toward a role for CLEC2 in macrophage function.
To further understand the potential mechanism leading to the im-
proved glucose and lipid homeostasis observed, we performed studies
with co-cultured Kupffer cells and hepatocytes. Our results demonstrate
that treatment of the co-culture with soluble CLEC2 improves measures
of liver oxidative phosphorylation and fatty acid oxidation. These data
suggest that hepatocytes may be a source of an endogenous ligand for
CLEC2. Furthermore, the local paracrine loop between hepatocytes
and Kupffer cellsmay also contribute to the improvementswe observed
in hepatosteatosis when diseased mice were given Fc-CLEC2(ECD)
treatment.
Although the results suggest that liver Kupffer cells are a potential
target for Fc-CLEC2(ECD)-mediated suppression of inﬂammation and
subsequent improvement of metabolic parameters, it remains possible
that this effect is indirect. In addition, it is important to note that there
may be additional Fc-CLEC2(ECD) targets. CLEC2 is expressed on the
surface of many myeloid cells including dendritic cells and neutrophils
(Mourao-Sa et al., 2011), thus, whether the improvedmetabolic pheno-
types induced by Fc-CLEC2(ECD) are due to its effects on the function of
CLEC2 receptor on those cells, or due to a gain-of-function effect inde-
pendent of the CLEC2 receptor, will require additional investigation.
In summary, using multiple in vitro and in vivo approaches we
identiﬁed a previously unknown connection between CLEC2 and Kupffer
cell activation. Our results demonstrate that the extracellular domain of
CLEC2 improves glucose homeostasis and hepatic steatosis in diabetic
mouse models. Our data support that targeting CLEC2 may be a promis-
ing new strategy for developing therapies for treating diabetes and possi-
bly steatotic liver diseases.
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